Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death

Manuela Basso, Huan Huan Chen, Debasmita Tripathy, Mariarosaria Conte, Kim Y.P. Apperley, Angela De Simone, Jeffrey W. Keillor, Rajiv Ratan, Angela Nebbioso, Federica Sarno, Lucia Altucci, Andrea Milelli

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In recent years there has been a clear consensus that neurodegenerative conditions can be better treated through concurrent modulation of different targets. Herein we report that combined inhibition of transglutaminase 2 (TG2) and histone deacetylases (HDACs) synergistically protects against toxic stimuli mediated by glutamate. Based on these findings, we designed and synthesized a series of novel dual TG2–HDAC binding agents. Compound 3 [(E)-N-hydroxy-5-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)pentanamide] emerged as the most interesting of the series, being able to inhibit TG2 and HDACs both in vitro (TG2 IC50=13.3±1.5 μm, HDAC1 IC50=3.38±0.14 μm, HDAC6 IC50=4.10±0.13 μm) and in cell-based assays. Furthermore, compound 3 does not exert any toxic effects in cortical neurons up to 50 μm and protects neurons against toxic insults induced by glutamate (5 mm) with an EC50 value of 3.7±0.5 μm.

Original languageEnglish
Pages (from-to)227-230
Number of pages4
JournalChemMedChem
Volume13
Issue number3
DOIs
Publication statusPublished - Feb 6 2018

Fingerprint

Histone Deacetylase Inhibitors
Poisons
Inhibitory Concentration 50
Histone Deacetylases
Neurons
Glutamic Acid
Assays
Modulation
transglutaminase 2

Keywords

  • histone deacetylase
  • hybrid compounds
  • multiple ligands
  • neurodegeneration
  • transglutaminase 2

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Organic Chemistry

Cite this

Basso, M., Chen, H. H., Tripathy, D., Conte, M., Apperley, K. Y. P., De Simone, A., ... Milelli, A. (2018). Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. ChemMedChem, 13(3), 227-230. https://doi.org/10.1002/cmdc.201700601

Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. / Basso, Manuela; Chen, Huan Huan; Tripathy, Debasmita; Conte, Mariarosaria; Apperley, Kim Y.P.; De Simone, Angela; Keillor, Jeffrey W.; Ratan, Rajiv; Nebbioso, Angela; Sarno, Federica; Altucci, Lucia; Milelli, Andrea.

In: ChemMedChem, Vol. 13, No. 3, 06.02.2018, p. 227-230.

Research output: Contribution to journalArticle

Basso, M, Chen, HH, Tripathy, D, Conte, M, Apperley, KYP, De Simone, A, Keillor, JW, Ratan, R, Nebbioso, A, Sarno, F, Altucci, L & Milelli, A 2018, 'Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death', ChemMedChem, vol. 13, no. 3, pp. 227-230. https://doi.org/10.1002/cmdc.201700601
Basso, Manuela ; Chen, Huan Huan ; Tripathy, Debasmita ; Conte, Mariarosaria ; Apperley, Kim Y.P. ; De Simone, Angela ; Keillor, Jeffrey W. ; Ratan, Rajiv ; Nebbioso, Angela ; Sarno, Federica ; Altucci, Lucia ; Milelli, Andrea. / Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death. In: ChemMedChem. 2018 ; Vol. 13, No. 3. pp. 227-230.
@article{5ad2c8af8cb5474baf67b51c0c03f295,
title = "Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death",
abstract = "In recent years there has been a clear consensus that neurodegenerative conditions can be better treated through concurrent modulation of different targets. Herein we report that combined inhibition of transglutaminase 2 (TG2) and histone deacetylases (HDACs) synergistically protects against toxic stimuli mediated by glutamate. Based on these findings, we designed and synthesized a series of novel dual TG2–HDAC binding agents. Compound 3 [(E)-N-hydroxy-5-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)pentanamide] emerged as the most interesting of the series, being able to inhibit TG2 and HDACs both in vitro (TG2 IC50=13.3±1.5 μm, HDAC1 IC50=3.38±0.14 μm, HDAC6 IC50=4.10±0.13 μm) and in cell-based assays. Furthermore, compound 3 does not exert any toxic effects in cortical neurons up to 50 μm and protects neurons against toxic insults induced by glutamate (5 mm) with an EC50 value of 3.7±0.5 μm.",
keywords = "histone deacetylase, hybrid compounds, multiple ligands, neurodegeneration, transglutaminase 2",
author = "Manuela Basso and Chen, {Huan Huan} and Debasmita Tripathy and Mariarosaria Conte and Apperley, {Kim Y.P.} and {De Simone}, Angela and Keillor, {Jeffrey W.} and Rajiv Ratan and Angela Nebbioso and Federica Sarno and Lucia Altucci and Andrea Milelli",
year = "2018",
month = "2",
day = "6",
doi = "10.1002/cmdc.201700601",
language = "English",
volume = "13",
pages = "227--230",
journal = "ChemMedChem",
issn = "1860-7179",
publisher = "John Wiley and Sons Ltd",
number = "3",

}

TY - JOUR

T1 - Designing Dual Transglutaminase 2/Histone Deacetylase Inhibitors Effective at Halting Neuronal Death

AU - Basso, Manuela

AU - Chen, Huan Huan

AU - Tripathy, Debasmita

AU - Conte, Mariarosaria

AU - Apperley, Kim Y.P.

AU - De Simone, Angela

AU - Keillor, Jeffrey W.

AU - Ratan, Rajiv

AU - Nebbioso, Angela

AU - Sarno, Federica

AU - Altucci, Lucia

AU - Milelli, Andrea

PY - 2018/2/6

Y1 - 2018/2/6

N2 - In recent years there has been a clear consensus that neurodegenerative conditions can be better treated through concurrent modulation of different targets. Herein we report that combined inhibition of transglutaminase 2 (TG2) and histone deacetylases (HDACs) synergistically protects against toxic stimuli mediated by glutamate. Based on these findings, we designed and synthesized a series of novel dual TG2–HDAC binding agents. Compound 3 [(E)-N-hydroxy-5-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)pentanamide] emerged as the most interesting of the series, being able to inhibit TG2 and HDACs both in vitro (TG2 IC50=13.3±1.5 μm, HDAC1 IC50=3.38±0.14 μm, HDAC6 IC50=4.10±0.13 μm) and in cell-based assays. Furthermore, compound 3 does not exert any toxic effects in cortical neurons up to 50 μm and protects neurons against toxic insults induced by glutamate (5 mm) with an EC50 value of 3.7±0.5 μm.

AB - In recent years there has been a clear consensus that neurodegenerative conditions can be better treated through concurrent modulation of different targets. Herein we report that combined inhibition of transglutaminase 2 (TG2) and histone deacetylases (HDACs) synergistically protects against toxic stimuli mediated by glutamate. Based on these findings, we designed and synthesized a series of novel dual TG2–HDAC binding agents. Compound 3 [(E)-N-hydroxy-5-(3-(4-(3-oxo-3-(pyridin-3-yl)prop-1-en-1-yl)phenyl)thioureido)pentanamide] emerged as the most interesting of the series, being able to inhibit TG2 and HDACs both in vitro (TG2 IC50=13.3±1.5 μm, HDAC1 IC50=3.38±0.14 μm, HDAC6 IC50=4.10±0.13 μm) and in cell-based assays. Furthermore, compound 3 does not exert any toxic effects in cortical neurons up to 50 μm and protects neurons against toxic insults induced by glutamate (5 mm) with an EC50 value of 3.7±0.5 μm.

KW - histone deacetylase

KW - hybrid compounds

KW - multiple ligands

KW - neurodegeneration

KW - transglutaminase 2

UR - http://www.scopus.com/inward/record.url?scp=85041736216&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041736216&partnerID=8YFLogxK

U2 - 10.1002/cmdc.201700601

DO - 10.1002/cmdc.201700601

M3 - Article

VL - 13

SP - 227

EP - 230

JO - ChemMedChem

JF - ChemMedChem

SN - 1860-7179

IS - 3

ER -